Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Elucid cardio imaging tech wins FDA clearance

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at massdevice.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Elucid has received FDA clearance for its AI-powered FFR-IQ software which noninvasively estimates fractional flow reserve from coronary CT angiography, aiding physicians in identifying patients needing invasive cardiac evaluation. The company also integrates FFR-IQ with Plaque-IQ into a comprehensive platform assessing coronary anatomy, physiology, and plaque biology to enhance personalised cardiology care.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Your cardiology AI product must now consider combining anatomy and physiological data into one tool to stay competitive. Elucid’s 510(k) clearance opens a path to replace invasive tests with AI-powered diagnostics that doctors want.

◆ Coverage

1 source · 26 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfda-clearancecardio-imagingai-healthtechnoninvasive-diagnostics